Q: I’m developing Parkinson’s disease. The symptoms are intermittent and mild, but I want to do everything I can to keep them that way. Can you let me know what ...

A Phase III, international, randomized clinical trial assessed the safety and efficacy of canagliflozin for the treatment of ...

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...

Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Eli Lilly (LLY) stock in focus as its diabetes drug Mounjaro causes heart benefits suceeding in a late-stage trial versus its ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs to curb their off-label use for weight loss and preserve supply for people who are diabetic.

British Columbia's Health Ministry is limiting the sales of two more diabetes drugs to curb their off-label use for weight loss and preserve supply for people who are diabetic.